FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,467,121 | -53.6% | 12,484,490 | +4.2% | 0.00% | -50.0% |
| Q2 2023 | $57,017,936 | -12.8% | 11,978,558 | +4.4% | 0.00% | 0.0% |
| Q1 2023 | $65,414,585 | -33.3% | 11,476,243 | +18.0% | 0.00% | -33.3% |
| Q4 2022 | $98,137,601 | -44.7% | 9,726,224 | +22.8% | 0.00% | -50.0% |
| Q3 2022 | $177,428,000 | -3.5% | 7,917,421 | +6.8% | 0.01% | 0.0% |
| Q2 2022 | $183,769,000 | -33.3% | 7,415,976 | +4.4% | 0.01% | -14.3% |
| Q1 2022 | $275,487,000 | -33.3% | 7,105,671 | +0.6% | 0.01% | -36.4% |
| Q4 2021 | $413,113,000 | +4.1% | 7,060,552 | +5.5% | 0.01% | 0.0% |
| Q3 2021 | $396,844,000 | -30.7% | 6,695,546 | +1.5% | 0.01% | -31.2% |
| Q2 2021 | $572,464,000 | -3.1% | 6,595,960 | -7.9% | 0.02% | -5.9% |
| Q1 2021 | $590,628,000 | -2.6% | 7,163,487 | +7.4% | 0.02% | -10.5% |
| Q4 2020 | $606,642,000 | +131.1% | 6,671,541 | +1.6% | 0.02% | +90.0% |
| Q3 2020 | $262,469,000 | +25.4% | 6,566,634 | +7.6% | 0.01% | +25.0% |
| Q2 2020 | $209,295,000 | +68.7% | 6,100,146 | +9.2% | 0.01% | +33.3% |
| Q1 2020 | $124,052,000 | +9.4% | 5,585,360 | -3.6% | 0.01% | +50.0% |
| Q4 2019 | $113,361,000 | +38.8% | 5,792,687 | +10.2% | 0.00% | +33.3% |
| Q3 2019 | $81,660,000 | -22.3% | 5,258,344 | +1.5% | 0.00% | -25.0% |
| Q2 2019 | $105,121,000 | +15.3% | 5,178,289 | -0.3% | 0.00% | 0.0% |
| Q1 2019 | $91,211,000 | +41.3% | 5,191,274 | +3.2% | 0.00% | +33.3% |
| Q4 2018 | $64,557,000 | +14.2% | 5,031,783 | +45.0% | 0.00% | +50.0% |
| Q3 2018 | $56,519,000 | +51.7% | 3,469,531 | +5.6% | 0.00% | 0.0% |
| Q2 2018 | $37,263,000 | +31.5% | 3,285,830 | +13.2% | 0.00% | +100.0% |
| Q1 2018 | $28,332,000 | +171.9% | 2,903,009 | +70.2% | 0.00% | – |
| Q4 2017 | $10,421,000 | +58.4% | 1,705,293 | +2.6% | 0.00% | – |
| Q3 2017 | $6,580,000 | +22.4% | 1,661,794 | +0.2% | 0.00% | – |
| Q2 2017 | $5,375,000 | +1271.2% | 1,658,727 | +1822.3% | 0.00% | – |
| Q1 2017 | $392,000 | – | 86,289 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |